Ergomed plc is a UK-based international provider specialist services to the pharmaceutical industry, founded in 1997. The company’s headquarters are in Guildford, Surrey, United Kingdom. The trust engaged in the business of providing of high-quality services to the pharmaceutical industry including drug development phases, medical information and post-approval pharmacovigilance. The company operates in two segments include drug safety and medical information services (DS&MI) and clinical research services (CRS). The company has its offices worldwide including United Kingdom, USA, Canada, The Netherlands, Germany, Switzerland, Spain, Poland, Russia, Czech Republic, Ukraine, Croatia, Serbia, Bosnia and Herzegovina, India, Bulgaria, and Japan.
The company is engaged in two businesses including Co-Development Business and Services Business and focused on immunology, oncology and neurology, and the development of orphan drugs. The company offers a range of clinical trial planning, monitoring and management services. The company’s engaged in clinical research business through its Services Business, it provides services to biotechnology and pharmaceutical industry. The company’s Co-Development Business is a portfolio of partnerships with biotechnology and pharmaceutical companies. It provides drug development services and engages in trial management, clinical development under the Ergomed brand (CRO) and pharmacovigilance services under the brand PrimeVigilance.
The company’s Ergomed brand (CRO) is designed to meet the needs of biotechnology and pharmaceutical companies. The company’s pharmacovigilance is provided by Prime vigilance which is a division of the company provided to achieve state of the art PV services. The company expands its business and operations by establishing a new regional office in Tokyo, Japan and focused on providing specialized services to the pharmaceutical industry include pharmacovigilance and medical information services. The company’s mission statement is to bring expertise to deliver medicines our world can trust.